Patent and Trademark Office. As of December 12, 1995, MicroCor's application for a patent entitled "Method and Apparatus for Non-Invasively Determining Hematocrit" was allowed by the U.S. Patent and Trademark Office, and such patent issued on June 18, 1996, as Patent No. 5,526,808 with a term of 17 years and an expiration date of June 18, 2013. MicroCor has been issued three additional patents, Patent No. 5,642,734, Patent No. 6,128,518 and Patent No. 6,766,191, each of which claims priority from October 4, 1990, the date of the first patent's filing, and each of which has an expiration date of October 4, 2010. Pursuant to a Development, Licensing and Manufacturing Agreement dated May 10, 2001 (the "2001 Agreement"), Chi Lxx xxx InMedica pursued additional development on the non-invasive hematocrit technology. The methods and procedures to measure hematocrit non-invasively, including without limitation, the patents and technologies incorporated in the patents and patent applications described above and the development work pursued by Chi Lxx xxx/or InMedica, are collectively referred to herein as the "Hematocrit Technology." InMedica is a publicly traded corporation. Chi Xxx xx a major shareholder of InMedica, owning one-third of the issued and outstanding shares of InMedica's common stock. MicroCor is a privately held corporation with 5,000,000 shares of common stock (the "MicroCor Stock") authorized under its Articles of Incorporation and no other class or series of stock authorized. InMedica and Chi Xxx xxx all of the issued and outstanding shares of the MicroCor Stock (147,101 shares), with InMedica owning 117,681 shares (80%) and Chi Lxx xxxxng 29,420 shares (20%). In order to facilitate further development of the Hematocrit Technology described in this Agreement, InMedica and Chi Lxx xxxxose to transfer, assign, or license their respective interests in the Hematocrit Technology to MicroCor. Wescor employs or has access to researchers and engineers to develop medical devices, equipment and products based on the Hematocrit Technology (the "Products"), and to conduct clinical trials of such products with the results thereof to be submitted to the U.S. Food and Drug Administration (the "FDA") to obtain clearance for marketing in the United States. It has the financial and managerial assets and experience to be capable of managing the process of developing and manufacturing the Products. The parties desire to enter into this Agreement with the intent of accomplishing the following pu...
Patent and Trademark Office. (xxxvii) The Guarantor and each of its subsidiaries maintains a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Guarantor’s most recent audited fiscal year, there has been (1) no material weakness in the Guarantor’s internal control over financial reporting (whether or not remediated) and (2) no change in the Guarantor’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Guarantor’s internal control over financial reporting.
Patent and Trademark Office. The security interest granted hereby has been granted to the Administrative Agent in connection with the Security Agreement and is expressly subject to the terms and conditions thereof and does not modify its terms or conditions or create any additional rights or obligations for any party thereto or hereto. The Security Agreement (and all rights and remedies of the Administrative Agent thereunder) shall remain in full force and effect in accordance with its terms.
Patent and Trademark Office. The United States Department of Commerce Patent and Trademark Office, Xxxxxxxxxx, XX 00000 and the Canadian Intellectual Property Office, Ottawa, Canada..
Patent and Trademark Office. The cost of such registration shall be borne equally by the parties. Grower and Winery shall jointly own the entire right, title and interest to such trademark. After the Name has been selected, Winery and Grower agree to enter into a Trademark License Agreement (the "Trademark Agreement") in the form attached hereto as Exhibit B, which agreement shall grant to Winery the right to use the selected trademark for wine. Pursuant to the Trademark Agreement, Winery shall be obligated to pay a fee in exchange for such right. Alternative #2 – Name Owned by Grower and Licensed to Winery:
Patent and Trademark Office. (a)(6) The estimated value of this Agreement is $1,600,000.00 and is broken down as follows: Line Number Item Value 1 Technical Data and Defense Services $1,100,000 Hardware 2 Permanent Export by DSP-5 or DSP-85 (Tooling/Support Equipment) $250,000.00 3 Permanent Export by DSP-5 or DSP-85 (Kits and Components N/A incorporated into manufactured items (MLA only) 4 Temporary Export by DSP-73 or DSP-85 Temporary $250,000.00 5 Import by DSP-61 or DSP-85 $0 6 Total Licensed Hardware (sum of lines 2, 3, 4 & 5) $500,000.00 7 Hardware value for Congressional Notification (line 2) $250,000.00 8 Hardware manufactured abroad (MLA Only) N/A 9 Agreement Total Value (Sum of lines 1, 6, & 8) $1,600,000.00 10 Congressional Notification Value (Sum of lines 1, 7 & 8) 1,350,000.00 This Agreement DOES or DOES NOT (select the one that applies) require Congressional Notification pursuant to §123.15 or §124.11.
Patent and Trademark Office. In May 2000, we created European operating entities to support our international operations and opened our first data center outside of the United States. Located in London, our European SmartCenter(SM) gives Digex customers in Europe the superior level of technology, security, and support services in Europe they have come to rely on in the United States. The data center is a leased facility which became operational in July 2000. In January 2001, we received a $3.0 million loan from the State of Maryland Department of Business and Economic Development under the Sunny Day Fund initiative which may convert into a grant if certain conditions are met at specific maturity dates. Also, in January 2001, we were recently ranked by Gartner Research, a leading industry research firm, as one of only two leaders on their North American Web Hosting Magic Quadrant, and placed as the most visionary company in the ranking.
Patent and Trademark Office. Amounts advanced under the Credit Facility shall be evidenced by a promissory note substantially in the form of Exhibit G attached hereto (the "Promissory Note").
Patent and Trademark Office. The Patents are valid and enforceable in accordance with their terms. Seller and each other party associated with the filing or prosecution of the Patents have met their duty to disclose information material to patentability in accordance with 37 CFR § 1.56. Except as asserted in connection with the Patent Litigation, neither the Company nor any Affiliate has received any notice that (a) the Patents infringe or otherwise conflict with the intellectual property rights of any third party or (b) any Patent is invalid or unenforceable. Except for the Contingency Arrangements and except as set forth herein, the Company has not granted any rights to the Infringement Claims to any Person and no Person is entitled to receive any portion of any Litigation Award. No consent, approval, filing, notification or other authorization of any Person is required for the granting of the rights hereunder to the Investors. No Person other than Seller has the right to consent to the settlement of any Patent Litigation.
Patent and Trademark Office. 1.2 The Escrow Agent shall hold and maintain the Reassignments and Clean Assignments in escrow hereunder until the first to occur of the following:
